Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Étude des Joints TRE sur les Sujets en Post-opératoire Précoce

9 novembre 2026 mis à jour par: Hollister Incorporated

Étude des Scellements TRE sur des Sujets en Phase Post-opératoire Précoce

This study will evaluate two Ostomy Seals/Rings in a group of post-operative patients.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Type d'étude

Interventionnel

Inscription (Estimé)

107

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • County Durham
      • Stockton-on-Tees, County Durham, Royaume-Uni, TS19 8PE
        • Recrutement
        • North Tees University Hospital
        • Contact:
    • East Sussex
      • Saint Leonards-on-Sea, East Sussex, Royaume-Uni, TN37 7RD
        • Recrutement
        • East Sussex Healthcare NHS Trust: Conquest and Eastbourne Hospitals
        • Contact:
    • Kent
      • Ashford, Kent, Royaume-Uni, TN24 0LZ
        • Recrutement
        • William Harvey Hospital
        • Contact:
      • Margate, Kent, Royaume-Uni, CT9 4AN
        • Recrutement
        • Queen Elizabeth The Queen Mother Hospital
        • Contact:
    • North Yorkshire
      • Middlesbrough, North Yorkshire, Royaume-Uni, TS4 3BW
        • Recrutement
        • South Tees University Hospital
        • Contact:
    • Surrey
      • Redhill, Surrey, Royaume-Uni, RH1 5RH
        • Recrutement
        • East Surrey Hospital
        • Contact:
    • West Midlands
      • Coventry, West Midlands, Royaume-Uni, CV2 2DX
        • Recrutement
        • University Hospital Coventry
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 85 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. At least 18 years of age
  2. Has their ostomy surgery and post-operative care in the United Kingdom (UK)
  3. Has a colostomy, ileostomy, or urostomy and no reversal planned during the study evaluation period
  4. Able to have first study product applied at first pouch change after surgery (or up to 4 days post-op)
  5. Is appropriate to use a barrier seal per the Investigator
  6. Able to provide an informed consent for study participation
  7. Willing to follow protocol procedures, including participating in study visits, as demonstrated by signing the informed consent

Exclusion Criteria:

  1. Is over 85 years of age
  2. Has received chemotherapy or radiation in the past 30 days or reports beginning chemotherapy or radiation during the study.
  3. A score of 1, 2, or 3 for any of the three OCSI Tool PSC-related domains (i.e., peristomal irritant dermatitis, peristomal bleeding, and hyperplasia) at time of enrollment
  4. Has a fistula in the peristomal area at time of enrollment
  5. Has an open draining wound (not including mucocutaneous separation) in the peristomal area at time of enrollment
  6. Has a suspected infection in the peristomal area at time of enrollment
  7. Is pregnant or lactating at time of enrollment (as determined by interview only)
  8. Is unable to speak, read, and understand English.
  9. Is currently participating in another clinical study using ostomy products
  10. Is currently an employee of Hollister Incorporated or any ostomy manufacturer

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Un Joint d'Iléostomie

An absorptive ostomy seal

Comparateur actif: Un anneau pour stomie

The Ostomy Ring contains Aloe

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
The Risk of Peristomal Skin Complications (PSCs) as measured using the three PSC-related questions on the Ostomy Complication Severity Index (OCSI)
Délai: From enrollment to the end of treatment at 9 weeks

The three PSC-related questions on the Ostomy Complication Severity Index (OCSI) are related to peristomal irritant dermatitis, peristomal bleeding, and hyperplasia. Each of these three items is rated on a scale of 0-3, with 0 indicating absence of the condition, and 3 indicating the condition is severe.

From enrollment to the end of treatment at 9 weeks

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Total Ostomy Complication Severity Index (OCSI) score and six stomal complication (non-PSC) domains of the OCSI and associated severity
Délai: From enrollment to the end of treatment at 9 weeks

Each of the OCSI items are scored on a scale of 0-3, with 0 indicating absence of the condition and 3 indicating the condition is severe.

From enrollment to the end of treatment at 9 weeks
Mediation of peristomal skin complications (PSCs) by leakage absorption measured using the leakage item on the Ostomy Complication Severity Index (OCSI)
Délai: From enrollment to the end of treatment at 9 weeks

The leakage item on the OCSI has a scale of 0 (no leakage) to 3 (leakage approximately 1-2 times per day)

From enrollment to the end of treatment at 9 weeks
Visible moisture/effluent on peristomal skin under the study seal area (OCSI Supplementary Question)
Délai: From enrollment to the end of treatment at 9 weeks

Assessed only if leakage is reported in the OCSI tool (conditional). Responses: Great amount / Slight amount / None (ordinal categorical).

From enrollment to the end of treatment at 9 weeks
Seal absorption of moisture/effluent under the study seal area (OCSI Supplementary Question)
Délai: From enrollment to end of treatment at 9 weeks

Participant response to whether the study seal absorbed moisture/effluent from around the stoma/peristomal skin under the seal. Responses: Yes / Somewhat / No, not at all (ordinal categorical).

From enrollment to end of treatment at 9 weeks
Presence of peristomal skin conditions (OCSI Supplementary Question)
Délai: From enrollment to end of treatment at 9 weeks

Checklist of skin conditions present: burning, itching, maceration, fungal rash, folliculitis, granuloma, mechanical trauma, product sensitivity/allergy, pyoderma gangrenosum, other, none.

From enrollment to end of treatment at 9 weeks
Peristomal skin burning severity (OCSI Supplementary Question)
Délai: From enrollment to end of treatment at 9 weeks

Rated on a numeric scale from 0 (absent) to 10 (worst burning imaginable). Assessed only if burning is reported (conditional logic from Q25). Higher scores indicate worse burning.

From enrollment to end of treatment at 9 weeks
Peristomal skin itching severity (OCSI Supplementary Question)
Délai: From enrollment to end of treatment at 9 weeks

Rated on a numeric scale from 0 (absent) to 10 (worst itching imaginable). Assessed only if itching is reported (conditional logic from Q25). Higher scores indicate worse itching.

From enrollment to end of treatment at 9 weeks
Time to resolution of peristomal skin complications (PSCs), assessed by the Ostomy Complication Severity Instrument (OCSI) at visits and adverse event (AE) reports between visits
Délai: From first PSC onset to resolution through end of treatment at 9 weeks

Unit of Measure: days

From first PSC onset to resolution through end of treatment at 9 weeks
Time to recurrence of peristomal skin complications (PSCs) after resolution, assessed by the OCSI at visits and AE reports between visits
Délai: From PSC resolution to first recurrence through end of treatment at 9 weeks

Unit of Measure: days

From PSC resolution to first recurrence through end of treatment at 9 weeks
Proportion of participants with PSC occurrence, PSC resolution, and PSC recurrence, assessed by the OCSI at visits and AE reports between visits
Délai: From enrollment to end of treatment at 9 weeks

Unit of Measure: percent (%)

From enrollment to end of treatment at 9 weeks
Patient satisfaction with the study Seal/Ring assessed using the Study-Specific Patient Satisfaction Questionnaire (Likert scale)
Délai: From enrollment to the end of treatment at 9 weeks

Rated on a 5-point Likert scale from 1 (Very Satisfied) to 5 (Very dissatisfied)

From enrollment to the end of treatment at 9 weeks
Clinician Satisfaction with the study Seal/Ring assessed using the Study-Specific Clinician Satisfaction Questionnaire (Likert scale)
Délai: From enrollment to the end of treatment at 9 weeks

Rated on a 5-point Likert scale from 1 (Very Satisfied) to 5 (Very dissatisfied)

From enrollment to the end of treatment at 9 weeks
Ability to correctly use the seal/ring with available instructional resources, assessed by the Study-Specific Instructional Resources Question
Délai: From enrollment to the end of treatment at 9 weeks

Single study-specific question assessing whether instructional resources (e.g., IFU, online guides) enabled correct use of the seal/ring; responses: Yes / No / Did not use instructional resources. Results will be reported as the proportion of participants in each response category.

From enrollment to the end of treatment at 9 weeks
Seal swelling/expansion incidence, assessed by Study-Specific Swell/Expand Question
Délai: From enrollment to the end of treatment at 9 weeks

Participant response comparing seal size at application versus at barrier change. Responses: No, seal did not swell/expand / Yes, seal swelled/expanded.

From enrollment to the end of treatment at 9 weeks
Effectiveness of seal swelling/expansion for secure fit against leakage, assessed by Study-Specific Swell/Expand Question
Délai: From enrollment to end of treatment at 9 weeks

Participant response regarding whether swelling/expansion provided a better, more secure fit against leakage. Responses: No, not at all / Yes, somewhat / Yes, definitely (ordinal categorical).

From enrollment to end of treatment at 9 weeks
Perceived moisture-wicking effect, assessed by the Study-Specific Moisture-Wicking Question (3-point scale)
Délai: From enrollment to the end of treatment at 9 weeks

Single study-specific question assessing perceived moisture-wicking away from peristomal skin. Responses: No, not at all / Yes, somewhat / Yes, definitely.

From enrollment to the end of treatment at 9 weeks
Clinician agreement with the study Seal/Ring performance assessed using the Study-Specific Clinician Agreement Questionnaire (Likert scale)
Délai: From enrollment to the end of treatment at 9 weeks

Rated on a 5-point Likert scale from 1 (Strongly agree) to 5 (Strongly disagree)

From enrollment to the end of treatment at 9 weeks
Quantity of seals/rings, barriers, and accessories used, assessed by Study-Specific Resource Utilization Log
Délai: From enrollment to the end of treatment at 9 weeks

Unit of measure: mean/median number used per participant (counts)

From enrollment to the end of treatment at 9 weeks
Wear/use time (longevity) of seals/rings and barriers, assessed by Study-Specific Resource Utilization Log
Délai: From enrollment to end of treatment at 9 weeks

Unit of measure: hours or days of wear time per application (time)

From enrollment to end of treatment at 9 weeks
Peristomal skin-related unplanned healthcare visits, assessed by Study-Specific Healthcare Utilization Question
Délai: From enrollment to end of treatment at 9 weeks

Unit of measure: number of visits per participant; optionally proportion with ≥1 visit (counts/%)

From enrollment to end of treatment at 9 weeks
Total ostomy seal/ring costs, derived from quantities recorded in the Resource and Healthcare Utilization Logs
Délai: From enrollment to end of treatment at 9 weeks

Unit of measure: currency (e.g., dollars)

From enrollment to end of treatment at 9 weeks

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chaise d'étude: John Whitaker, University Hospital Coventry

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

30 juin 2026

Achèvement primaire (Estimé)

1 mars 2027

Achèvement de l'étude (Estimé)

1 mars 2027

Dates d'inscription aux études

Première soumission

25 février 2026

Première soumission répondant aux critères de contrôle qualité

3 mars 2026

Première publication (Réel)

10 mars 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 novembre 2026

Dernière vérification

1 juillet 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 6042-OST

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner